Most prostate cancers detected today are slow growing, early, localized cases that have minimal risk of harming the patient. Accurate identification of very low- and low-risk patients at initial diagnosis is a major challenge due to imperfect risk-stratification tools, particularly biopsy errors and high inter-observer variability among pathologists. Despite an error rate of 40 per cent in distinguishing between low risk and intermediate risk patients, deferred treatment (active surveillance) is now the official recommendation of Canadian urologists for patients diagnosed with low grade cancers. Inability to accurately identify high grade elements on core needle biopsies makes active surveillance (AS) challenging and results in up to a third of men on AS protocols converting to radical treatment each year. Dr. Tamara Jamaspishvili’s research interest and the project goals are to identify and validate promising diagnostic and prognostic biomarkers for early prostate cancer that may be used as complementary tests by pathologists to identify subset of cancers with hidden aggressive nature.
|2015 -||Transformative Pathology Fellow, Transformative Pathology, Ontario Institute for Cancer Research (OICR).|
|2012 - 2015||Postdoctoral fellow, Department of Pathology & Molecular Medicine, Queen’s University.|
|2008 - 2011||Clinician scientist, Department of Clinical & Molecular Pathology, Medical Faculty, Palacky University.|
|2007 - 2011||PhD, Department of Clinical & Molecular Pathology, Faculty of Medicine, Palacky University.|
|2005 - 2007||Trainee in Anatomic Pathology , Department of Pathology, Central University Clinic.|
|2005 - 2006||Resident in Laboratory Medicine, Department of Laboratory Medicine, Tbilisi State Medical University.|
|2004||Trainee in Diagnostic Cytopathology and Cytogenetics, Department of Clinical Cytogenetics, Tbilisi State Hematology Institute.|
|1998 - 2004||MD, Faculty of General Medicine, Tbilisi State Medical University.|
- Troyer DA, Jamaspishvili T, Wei W, Feng Z, Good J, Hawley S, Fazli L, McKenney JK, Simko J, Hurtado-Coll, Carroll PR, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, True LD, Brooks JD, Squire JA.
A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
- Prostate. Aug 1;75(11):1206-15; 2015
- Tamara Jamaspishvili and Jeremy A Squire.
Moving discoveries from cancer genomics research lab into pathology practice.
- George J. Netto, Iris Schrijver (ed) Genomic Applications in Clinical and Anatomic Pathology. Springer, New York; 2013
- Jamaspishvili T, Kral M, Khomeriki I, Vyhnankova V, Mgebrishvili G, Student V, Kolar Z, Bouchal J.
Quadriplex model enhances urine-based detection of prostate cancer.
- Prostate Cancer Prostatic Dis. Dec;14(4):354-60; 2011
- Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J.
Urine markers in monitoring for prostate cancer.
- Prostate Cancer Prostatic Dis. Mar;13(1):12-9; 2010